

**BOOK NOW & SAVE
UP TO \$499**

June 11-13, 2019 | Pudong, Shanghai, China
www.worldadc-asia.com



“The first World ADC Asia was a great success. It was a great opportunity for many people like myself to grasp what is going on in the field within the region, whilst comparing with the rest of the world”

Shanghai ChemPartner Co. Ltd

Maximize the Therapeutic Index of Your ADC Candidate

26 Expert Speakers Include:



Amy Han
Director of
Chemistry Research
& Development
Regeneron



Takashi Nakada
Researcher
Daiichi Sankyo



Youling Wu
Chief Executive
Officer
Teruishi



Nianhe Han
Chief Executive
Officer
**NewBio
Therapeutics**



**Toshimitsu
Uenaka**
Head, Oncology
Biologics
Laboratory
Eisai

Lead Partner:



Levena
Biopharma

Senior Partners:



MabPlex

Antibody Drug Conjugates @World_ADC #World_ADC **www.worldadc-asia.com**

Tel: +44 203 141 8700 **US:** +1 415 735 3289 **Email:** adc@hansonwade.com



hansonwade

Welcome to the 2nd World ADC Asia

The 2nd Annual World ADC Asia will enable you to maximize the therapeutic window of your ADC candidate

Solely dedicated to antibody drug conjugate (ADC) drug development, with leading insight from 25 expert speakers, the **2nd World ADC Asia** will enable you to **propel your ADC candidate into clinical development; with a specific focus for Asia.**

Designed with **Immunogen, Daiichi Sankyo** and **Eisai**, World ADC Asia will provide you with the most cutting-edge scientific advances on;

- Exploring targets beyond HER-2 to **expand your ADC pipeline** and explore novel innovations
- **Confidently meeting Chinese FDA regulatory** requirements to submit a successful IND package and translate into the clinic
- Optimizing ADC CMC processes **to simplify manufacturing processes**

Join 120+ of your industry peers from the **world's leading ADC companies** at this forum to network with potential collaborators and further cement existing partnerships. Hear the latest on key challenges such as working with regulatory bodies, submitting an IND and manufacturing; all with a specific focus for Asia.

For ADC drug developers like you this will be your **ultimate learning** and **networking** experience of 2019.

What Previous World ADC Attendees Have Said:

“This conference is an unique opportunity to talk about ADCs deeply. It was really fruitful”

Daiichi Sankyo

“Reports from the early clinical trials indicate that ADCs are setting the bar very high for eliminating cancer and the conference emphasized this exciting development”

Eisai

“World ADC was an opportunity to have face time with the industry leaders in ADCs and converse in a cooperative, sharing and constructive environment”

Genentech



Top 5 Reasons to Attend World ADC Asia:


1.

Learn the experience of operating a clinical trial in China to **maximize your trials and improve your current practice** with **Miracogen**




2.

Explore the current landscape of ADCs to get an **understanding of the trials being conducted in Asia** and the rest of the world with **Beacon Targeted Therapies**




3.

Review the latest and most exciting data from phase 1 clinical trials **to ensure safe and effective clinical development** with **Eisai**




4.

Share lessons learned when working with regulatory bodies to ensure you are **submitting a successful and cohesive IND package** with **Blissbio** and **Ambrx**



5.

Develop robust and scalable processes for ADC manufacturing by optimizing and simplifying processes with **TOT Biopharm**



26 Expert Speakers



Amy Han
Director of Chemistry
Research & Development
Regeneron



Dian Su
DMPK Scientist
Genentech



Feng Tian
Chief Executive Officer
Ambix



Gang Qin
Chief Executive Officer
GeneQuantum



George Badescu
Vice President Scientific
Affairs
Heidelberg



Hui Li
Chief Executive Officer
Levena



Ian Schwartz
Technology Consultant,
Bioconjugation
Sartorius Stedim



Jian Wang
Senior Principle Scientist
BMS




Jianmin Fang
Chief Executive Officer
Remegen



Koji Ushioda
Chief Executive Officer
SKAN



Kristine Kim
Professor
**Kangwon National
University & KFDA**




Letrishka Antony
Senior Analyst
Beacon



Xinfang Li
Vice President - Process
Development & Head of
Chemistry, Manufacturing
& Controls
Mabplex



Mary Hu
Chief Executive Officer
Miracogen



Ming Lu
Professor
**Guangzhou Medical
University**



Nianhe Han
Chief Executive Officer
Newbio Therapeutics



Richard Denk
Head of Sales
Containment
SKAN



Rick Powers
ADC Consulting
Independent Consultant



Takashi Nakada
Researcher
Daiichi Sankyo



Toshimitsu Uenaka
Head, Oncology Biologics
Laboratory
Eisai



Tse-Wen Chang
Chief Executive Officer &
President
Immunwork



Xiaomai Zhou
Vice President
DAC Biotech



Ying Buechler
Vice President of
Development
Ambix



Youling Wu
Chief Executive Officer
Teruisi



Ziping Wei
Chief Executive Officer
BlissBio

Conference Day 1 | Wednesday June 12, 2019

Mary Hu Chief Executive Officer Miracogen	8.50 Chair's Opening Remarks
Letrishka Antony Senior Analyst Beacon	9.00 Keynote: Antibody Drug Conjugate Development in Asia: Current Clinical Status & Future Directions - Update on the key movements in the clinic - Insight into the rapidly evolving pipeline - Analysis of novel clinical ADCs
Takashi Nakada Researcher Daiichi Sankyo	9.30 Keynote: Daiichi Sankyo DXd ADC Technology: DS-8201 & U3-1402: Clinical Validation of an ADC Design Meant to Deliver a By-Stander Effect - Design of novel drug-linker technology based on topo-I inhibitor Exatecan - Highly efficacious ADC with high DAR, bystander effect, and excellent stability in systemic circulation - Clinical outcomes of DS-8201a, U3-1402 and other ADCs
Hui Li Chief Executive Officer Levena	10.00 Designing Novel ADCs Against Multiple Myeloma - Levena has developed synthetic chemistry based site-specific conjugation methods, K-Lock & C-Lock, together with its proprietary toxin Duostatin - Novel ADCs against CD-38 and BCMA, based on Levena's technology, have been developed for targeting multiple myeloma and demonstrated good efficacy and safety profiles - These ADCs have been CMC enabled and are currently under IND enabling studies
	10.30 Speed Networking This session is a great opportunity to introduce yourself to the attendees that you would like to have more in depth conversations with. This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the ADC field and establish meaningful business relationships.
	11.30 Morning Refreshments

Discovery & Development Stream Chair: Tse-Wen Chang , CEO, Immunwork	CMC & Regulatory Stream Chair: Firelli Alonso , Senior Director, External Supply, Pfizer
Effectively Translating into the Clinic	Reducing Manufacturing Costs Whilst Increasing Efficacy
12.30 Discussing an Overview of the ADC field and Lessons Learned from Translating into The Clinic - Reviewing the preclinical ADC landscape - Sharing lessons learned from translating into phase I - Reflecting on the landscape and the next steps for ADCs Feng Tian , Chief Executive Officer, Ambrix	12.30 Conjugation & Fill Finish: How to Secure the Supply Chain of ADCs - Overview of the supply chain - Driving a clinical product to the BLA - Setting a robust commercial supply Giorgio Salciarini , Technical Business Development Manager, BSP Pharmaceuticals
1.00 Breast Cancer Subtype-Specific Biomarker Identification By Phenotypic Selection - For the discovery of diagnostic and therapeutic targets, we have developed a systematic approach for concurrent identification of Antibody and Antigen (Ab/Ag) pairs. - In this presentation, the technical platform for the discovery of Ab/Ag pairs for molecular subpopulation of breast cancers will be presented. - The potential value of the Ab/Ag pair for diagnostic, therapeutic biomarkers, and cancer therapy as antibody and antibody drug conjugate will be presented using the Ab/Ag identified using the platform as an example Kristine Kim , Professor, Kangwon National University	1.00 ADC Manufacturing: ADC Outsourcing, Technology Transfer & CMO-Client Relationships - How to choose the right CMO when outsourcing - Guide you through the contractual agreement - Understand the key elements to develop a partnership between the parties, covering all phases

1.30 Lunch & Networking

Sharing Novel & Innovative Technology Approaches

2.30 Amanitin-based Antibody-Drug Conjugates as New Therapeutic Modalities for Cancer Therapy

- Antigen-Targeted Amanitin-Conjugates (ATACs) represent a new class of ADCs using the payload Amanitin
- This payload introduces a novel mode of action into oncology therapy, the inhibition of RNA polymerase II
- The technology platform includes Amanitin supply, site-specific conjugation, demonstrated safety profile and biomarker
- HDP-101 is the first ATAC directed against BCMA entering Phase I trials by the end of 2019

George Badescu, Vice President Scientific Affairs,
Heidelberg Pharma

3.00 New Linker Technology & Next-generation of ADCs

- ADC overview
- NBT's site-specific conjugation technology
- Case studies of ADC discovery with site-specific conjugation technology

Nianhe Han, Chief Executive Officer, **NewBio Therapeutics**

Sharing Lessons Learned from Experience with Regulatory Bodies

2.30 Lessons Learned from Preparation of an IND Submission in US & China

- Outline the differences of regulatory expectation of Phase 1 submission of ADC in US and China
- Address the challenges of dual submission of Phase 1 IND package of an ADC molecule in US and China
- Share the lessons learned from the preparation of the CMC, pre-clinical and clinical development package of an ADC molecule

Ziping Wei, Chief Executive Officer, **BlissBio**

3.00 ARX788 Manufacturing & Comparability Strategy Meeting Regulatory Requirements

- Introduction to Ambrx technology
- Advantage of applying Ambrx technology to make ADCs
- ARX788 development and manufacturing strategy
- ARX788 comparability strategy and study results addressing process changes

Ying Buechler, Vice President of Development, **Ambrx**

3.30 Afternoon Refreshments & Networking

Optimization of ADCs: Maximizing the Therapeutic Window of Your ADC Candidate

Jianmin Fang
Chief Executive
Officer
Remegen

4.10 Overcoming Challenges of Maximizing the Clinical Therapeutic Window of Antibody Drug Conjugates Case Study: RC48ADC

- Optimizing clinical trial design
- Overcoming operational challenges within Asia
- Delving into RC48ADC

Amy Han
Director of Chemistry
Research &
Development
Regeneron

4.40 Discovering ADC for Potential Treatment of Prostates Cancer

- Discover novel tubulysins that potentially kill multiple MDR celllines
- Develop site-specific tubulysin ADC
- Demonstrate in vitro activity and in vivo efficacy in prostate models

Mary Hu
Chief Executive
Officer
Miracogen

5.10 Chair's Closing Remarks



5.20 Scientific Poster Session

After the formal presentations have finished, the learning and networking carries on. The Poster Session is an informal part of the conference agenda, allowing you to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships.

Conference Day 2 | Thursday June 13, 2019

Mary Hu Chief Executive Officer Miracogen	8.50 Chair's Opening Remarks
Discovering Novel & Lower Potency Payloads	
Dian Su DMPK Scientist Genentech	9.00 Unveiling Complex & Novel Biotransformations of Antibody Drug Conjugates Bearing CBI Dimer Payloads - Complex and novel biotransformations of CBI ADCs - Impact of biotransformations on in vitro potency, in vivo efficacy and bioanalysis of CBI ADCs - In vitro assay for predicting CBI ADC biotransformations - Means for modulating CBI ADC biotransformations
Gang Qin Chief Executive Officer GeneQuantum	9.30 Endeavour to Successfully Develop Efficacious & Safe Next-generation ADCs - Rational design of ADC molecule - iLDC: Simple and efficient continuous conjugating platform - Outstanding homogeneity and stability - Optimized TI - Best-in-class / First-in-class potential for various solid tumor targeting candidates
10.00 Morning Refreshments & Networking	

Discovery & Development Stream Chair: Tse-Wen Chang , CEO, Immunwork	CMC & Regulatory Stream Chair: Firelli Alonso , Senior Director, External Supply, Pfizer
Exploring Novel Targets & Moving Beyond HER	Delving into Analytical Considerations For CMC
11.00 Development of Innovative ADCs Targeting Solid Tumors - Screening and identifying linker-payload pairs that are both more efficacious and safer than MCC-DM1 - These linker-payload pairs maintain these superior properties when conjugated to a variety of antibodies - Encouraging preclinical results of novel ADCs toward a list of non-Her2 targets Xiaomai Shou , Vice President, DAC Biotech	11.00 What we Learnt from the Failed ADCs & Strategy to Make a Better One - What we learnt from the failed ADCs - What strategy to make a better one - Does antibody binding affinity influence ADC fate? - Does conjugation format affect the internalisation? Mabplex, Speaker TBC
11.30 Exploring Novel ADC Drug Targets & Molecular Mechanisms Using An In Vitro Liver Differentiation Model - Investigation of stem cell differentiation process might provide novel therapeutic candidates for ADC drug development - Targeting the developmental signaling pathways might provide novel therapeutic strategy in cancer treatment Ming Lui , Professor, Guangzhou Medical University	11.30 Addressing Limitations in Resources to Improve Preclinical Candidates - Overcoming manufacturing resource challenges - Learn how to set up and manage complex supply chain networks efficiently - Simplifying processes to overcome manufacturing challenges

12.00 Lunch & Networking

Revealing Successful Results from Companies with Candidates in the Clinic

Toshimitsu Uenaka Head, Oncology Biologics Laboratory Eisai	1.30 Assessing Phase 1 interim Data of MORAb-202, a Folate Receptor Alpha-Targeted Antibody-drug Conjugate - MORAb-202 is the first ADC which is loaded with HALAVEN® as payload - HALAVEN® is an approved drug which exhibits unique effects on tumor microenvironment - The interim data of MORAb-202 Phase 1 study in Japan is to be discussed
Mary Hu Chief Executive Officer Miracogen	2.00 Reviewing the Clinical Experience of Operating a Trial in China: MRG003 - Selection of clinical investigators and sites is critical - IRB and HGRAC approval must be obtained prior to clinical studies - Close communication and oversight are essential for quick enrollment
	2.30 Afternoon Refreshments & Networking

Discovering Innovative Therapeutic Approaches for ADCs

Youling Wu Chief Executive Officer Teruishi	3.30 Session TBC
Tse-Wen Chang Chief Executive Officer & President Immunwork	4.00 Branching Out From Traditional ADCs – Small Molecule Drug Conjugates 3 to 5 chelator molecules or cytotoxic drug molecules (effector elements) are prepared in bundles based on novel multi-arm linkers - The effector bundles are conjugated to an antibody molecule or to a bundle of small molecules (a targeting bundle) - One ADC and one SMDC conjugated with DOTA chelator bundles subjected to CMC development are to be discussed
Mary Hu Chief Executive Officer Miracogen	4.30 Chair's Closing Remarks

Conference was excellent. A lot of speakers from different occupational backgrounds that shed light on different challenges faced

Vertex

Pre-Conference Workshops | Tuesday June 11, 2019

CHOOSE

Workshop A

Advanced Design of ADCs: Principles & Applications with Next Generation Linkers & Site-Specific Technology

9:00am – 12:00pm

Let's explore various ways to improve the therapeutic window of ADCs using a rational approach to improve clinical performance by building a better molecule. By incorporating improvements in solubility as well as attachment stability, great strides can be made. We will discuss various methods for obtaining a defined DAR, and the pros and cons of several key approaches. Also, attention will be given to dual and multi-warhead ADCs, and the various ways to achieve controlled multi-valency on native and engineered proteins. Lastly, with the emergence of Immuno-oncology, dual binding bi-specific antibodies will be discussed as a platform for ADC conjugations.

Chapters Summary

- 1) Welcome and Introductions
- 2) Background and Defining the Challenge
- 3) Solubilizing the Drug-Linker
- 4) Stabilizing the Linker
- 5) Site-Specific Strategies for Success
- 6) Multi-valency and Dual-Warheads
- 7) Bi-specific constructs as ADC platforms

Workshop Leader



Rick Powers
ADC Consulting
Independent Consultant

OR

Workshop C

Antibody Drug Conjugate process development and manufacturing from Conjugation to Fill & Finish

9:00am – 12:00pm

A robust and scalable platform for ADC process development and manufacturing will be presented during the Workshop. Isolator Dispensing for the toxin and single-use process technologies to accelerate development timelines and increase manufacturing predictability while decreasing scale up risks will be discussed. Case studies of single use ADC purification technologies will be presented. Additionally, the chemical compatibility of the materials described in ADC manufacturing platform to solvents typically used in ADC processing will be described. The workshop does also cover the Aseptic Fill & Finish part in Isolators, Cleaning and Cross Contamination requirements as well as Occupational safety for the operators.

Workshop Leaders



Richard Denk
Head of Sales Containment
SKAN



Koji Ushioda
Chief Executive Officer
SKAN



Ian Schwartz
Technology Consultant, Bioconjugation
Sartorius Stedim

Workshop B

Covering All Aspects Analysis & Bioanalysis of Antibody Drug Conjugates

1:00pm – 4:00pm

- Technical challenges in ADC analytical characterization and bioanalysis
- Recent advancement in technologies and strategies and an update of regulatory perspectives
- Selection and correlation of various technologies and platforms in ADC bioanalysis
- The trend and future: discovery and development integrated bioanalytical strategy
- Stage specific and continuity of bioanalytical approaches, platforms and strategies at different phases of ADC development
- Recommended strategy in choosing ADC analytes, assay platforms and assay DAR characteristics
- Discussion on regulatory requirements
- Challenges and strategies of bioanalysis for new conjugate modalities

Workshop Leaders



Dian Su
DMPK Scientist
Genentech



Jian Wang
Senior Principle Scientist
BMS

Partnership Opportunities

Partner with World ADC Asia


Partnering with **World ADC** is the perfect platform to demonstrate your expertise in ADC drug development. It's **your opportunity** to showcase your **brand**, your **message** and your **reputation** to the leading minds located in Asia prioritizing ADC development.

After last year's success, the 2nd annual forum will bring together industry experts within the drug development community. This is an unique opportunity for you to demonstrate how your company can enable drug developers to overcome the barriers in **maximizing the clinical therapeutic window of ADCs within Asia**.

This could involve presenting on the agenda, hosting networking sessions, exhibiting, or brand exposure. But our focus and reach is much wider, **we'll work with you to build a bespoke partnership to help ensure you meet your 2019 business objectives**. From being fully integrated across a multi-channel global communication strategy, to targeted introductions to the right individuals in your target market, we have opportunities that offer it all.


Contact us today to find out how we can help you achieve your business goals faster
adc@hansonwade.com

Seniority of Attendees*



Director
C-Level
Manager
Scientist
President/VP
Professor
Other
Senior Manager

Attendees by Geo*



*Based on World ADC Asia 2018

Companies Who Attend World ADC Asia



Contact us today to find out how we can help achieve your 2019 business goals faster



Rob Keast
Commercial Director
Tel: +44 203 141 8700
Email: adc@hansonwade.com

Our 2019 Partners

Lead Partner



Senior Partner



MabPlex 迈百瑞

Partners



sartorius



Exhibitor



ADCBIO



BrightGene

**Contact us today to find out
how we can help achieve your
2019 business goals faster**



Rob Keast

Commercial Director

Tel: +44 203 141 8700

Email: adc@hansonwade.com

Ready to Register?

3 Easy Ways to Book

 www.worldadc-asia.com/register

 Tel: +1 415 735 3289

 Email: adc@hansonwade.com

- 1 Immerse yourself in cutting-edge ADC science and hear the latest data, insight and lessons learned to power the development of your lead candidate
- 2 Gain lessons learned on filing a successful IND to regulatory bodies and effectively translate into the clinic
- 3 Explore novel ADC technologies to enhance your ADC pipeline and maximize the therapeutic index of your ADC candidate

Team Discounts*

- 20% discount – 3 or more delegates
- 10% discount – 2 delegates


Please note that discounts are only valid when three or more delegates from one company book and pay at the same time. Contact: register@hansonwade.com

Secure Your Place

Companies Based in Asia	Offer Ends April 12	Standard Prices
Conference Only	\$899 (save \$200)	\$1099
Premium Package (conference plus 2 workshops)	\$1099 (save \$399)	\$1299 (save \$199)
International Companies	Offer Ends April 12	Standard Prices
Conference Only	\$1899 (save \$400)	\$2299
Premium Package (conference plus 2 workshops)	\$2899 (save \$499)	\$3299 (save \$99)

*Applicable for organizations headquartered in Asia

**10% WHT will be added if the company registering is a Chinese-based business



Venue

Wyndham Grand Plaza Royale Oriental Shanghai
2288 Pudong Avenue Shanghai
China, 200136

[Click here to visit website](#)

Visas

If you or one of your colleagues require a letter of invitation to support a visa application to attend, please send us your request by March 25, 2019. If having an original copy of this visa letter is necessary for your application, please let us know at the time of request.

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH

Code: 9695